Table 1.
Socio-demographics and clinical characteristics of the cohort sample.
|
All patients (N = 16) |
|
|---|---|
| Age, years mean (SD) | 43.8 (8.7) |
| Sex | |
| • Female, n (%) | 14 (87.5) |
| • Male, n (%) | 2 (12.5) |
| Working status | |
| • Employed, n (%) | 13 (81.2) |
| • Retired, n (%) | 1 (6.3) |
| • Unemployed, n (%) | 2 (12.5) |
| Relationship status | |
| • Single, n (%) | 3 (18.8) |
| • In a relationship, n (%) | 2 (12.5) |
| • Married, n (%) | 11 (68.7) |
| Living situation | |
| • Living independently in a household (with spouse or significant other) | 13 (81.2) |
| • Living in residence with a family member (not spouse or significant other) | 3 (18.8) |
| Highest level of education | |
| • Secondary school, n (%) | 1 (6.3) |
| • University, n (%) | 15 (93.7) |
| Smoker, n (%) | 1 (6.3) |
| Family history of migraine, n (%) | 7 (43.8) |
| Referral to a neurologist, n (%) | |
| • Alone | 6 (37.5) |
| • GP | 2 (12.5) |
| • Other | 8 (50.0) |
| Chronic concurrent preventative medication with erenumab, n (%) | |
| • None | 4 (25) |
| • Erenumab as second line of treatment | 7 (43.8) |
| • Erenumab as third line of treatment | 5 (31.3) |
| Use of triptans, n (%) | |
| • At some point in their life | 16 (100.0) |
| • At onset of erenumab treatment | 9 (56.3) |
| • Stopped during erenumab treatment | 1 (6.3) |
| Patients fulfilling the criteria of medication-overuse headache (MOH) (%) | 14 (87.5) |
| • Conversion of MOH after at least 6 months of erenumab treatment | 8 (57.1) |